Mirum Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 92.00 +6.96%
Mirum Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Mirum Pharmaceuticals generated -$44.3 million of operating cash flow and spent $23,000 on capital expenditures. That left free cash flow of -$44.3 million, a free-cash-flow margin of -25.1% of revenue. Free cash flow was down 471.6% from the prior year's $11.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
Mirum Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -67.23M | -790.15M | -5.73M | 2.90M | -5.86M | -14.68M | -23.79M | -14.23M | -24.64M | -25.28M | -35.66M | -23.59M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 6.94M | 6.87M | 6.07M | 6.06M | 6.06M | 6.05M | 6.06M | 6.05M | 5.85M | 5.66M | 5.49M | 2.66M |
| Stock-Based Compensation | 30.57M | 36.20M | 19.03M | 18.13M | 18.47M | 15.80M | 13.25M | 11.91M | 11.84M | 11.45M | 9.72M | 8.38M |
| Change in Working Capital | -19.18M | -19.60M | -22.93M | -6.99M | -12.65M | -19.60M | -11.08M | -10.41M | -6.62M | 12.02M | -19.59M | -13.00M |
| Operating Cash Flow | -44.25M | -228.76M | 6.07M | 39.68M | 12.04M | -1.96M | -5.07M | 3.98M | -3.80M | 15.21M | -16.62M | -18.22M |
| Capital Expenditures | -23.00K | -664.00K | -600.00K | -187.00K | -126.00K | -41.00K | -20.00K | -181.00K | -779.00K | -13.00K | 0 | 0 |
| Investing Cash Flow | -159.99M | -11.57M | 1.01M | -2.23M | -6.60M | -16.13M | 641.00K | -18.04M | -72.72M | -13.00K | -2.00M | -182.76M |
| Financing Cash Flow | 211.44M | 270.08M | 9.00M | 16.10M | 8.69M | 6.36M | 5.34M | 3.86M | 7.29M | 1.21M | 1.78M | 207.13M |
| Net Change in Cash | 5.82M | 28.48M | 15.66M | 53.90M | 16.36M | -10.68M | -466.00K | -10.10M | -69.35M | 16.52M | -16.73M | 5.83M |
| Free Cash Flow | -44.27M | -229.43M | 5.47M | 39.49M | 11.91M | -2.00M | -5.09M | 3.80M | -4.58M | 15.20M | -16.62M | -18.22M |
This table shows 12 quarterly periods of Mirum Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MIRM's reporting calendar. What is a cash flow statement?